Fortress Biotech, Inc. (FBIO)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 20M 40M 60M Q3 '16: 975K Q4 '16: 12.6M Q1 '17: 44.7M Q2 '17: 50.7M Q3 '17: 46.9M Q4 '17: 7.5M Q1 '18: 5.9M Q2 '18: 6.8M Q3 '18: 5.2M Q4 '18: 9M Q1 '19: 6.5M Q2 '19: 9.2M Q3 '19: 9.8M Q4 '19: 11.1M Q1 '20: 12.9M Q2 '20: 9.5M Q3 '20: 9.5M Q4 '20: 13.7M Q1 '21: 11.6M Q2 '21: 17.8M Q3 '21: 21.1M Q4 '21: 18.3M Q1 '22: 23.9M Q2 '22: 18.9M Q3 '22: 16.5M Q4 '22: 16.4M Q1 '23: 12.4M Q2 '23: 17.4M Q3 '23: 34.8M Q4 '23: 19.9M Q1 '24: 13M Q2 '24: 14.9M Q3 '24: 14.6M Q4 '24: 15.1M Q1 '25: 13.1M Q2 '25: 16.4M Q3 '25: 17.6M Q4 '25: 16.1M Q1 '26: 16M Q2 '26: 18.7M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit Quarterly

0 700K 1.4M 2.1M Q2 '15: 0 Q3 '15: 25K Q2 '16: 1.9M Q3 '16: 934K Q2 '15 Q3 '15 Q2 '16 Q3 '16

Operating Income Quarterly

-75M -50M -25M 0 25M 50M 75M Q3 '16: -16.2M Q4 '16: -32.2M Q1 '17: -17.6M Q2 '17: -23.2M Q3 '17: -32.6M Q4 '17: -30.6M Q1 '18: -34.2M Q2 '18: -25.4M Q3 '18: -28.2M Q4 '18: -41.2M Q1 '19: -32.6M Q2 '19: -25.3M Q3 '19: -22.5M Q4 '19: -30.4M Q1 '20: -21.5M Q2 '20: -25.4M Q3 '20: -23M Q4 '20: -24.3M Q1 '21: -30M Q2 '21: -42.9M Q3 '21: -49.9M Q4 '21: -62M Q1 '22: -47.3M Q2 '22: -50.9M Q3 '22: -50.7M Q4 '22: -54.6M Q1 '23: -58.9M Q2 '23: -50.1M Q3 '23: -13.8M Q4 '23: -19.6M Q1 '24: -36.6M Q2 '24: -27.8M Q3 '24: -22.1M Q4 '24: -23.8M Q1 '25: -22.3M Q2 '25: -36.5M Q3 '25: -6.8M Q4 '25: -4.8M Q1 '26: -7.7M Q2 '26: -10M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income Quarterly

-40M 0 40M 80M 120M Q3 '16: -13M Q4 '16: -17.4M Q1 '17: -12M Q2 '17: -17.4M Q3 '17: -27.1M Q4 '17: -10.4M Q1 '18: -21M Q2 '18: -21.6M Q3 '18: -16.6M Q4 '18: -24.9M Q1 '19: 1.4M Q2 '19: -13.1M Q3 '19: -12.8M Q4 '19: -15.5M Q1 '20: -12.4M Q2 '20: -13.3M Q3 '20: -15.5M Q4 '20: -5.3M Q1 '21: -8.8M Q2 '21: -3.5M Q3 '21: -20.8M Q4 '21: -31.6M Q1 '22: -15.8M Q2 '22: -21.4M Q3 '22: -22.5M Q4 '22: -26.9M Q1 '23: -21.5M Q2 '23: -24.8M Q3 '23: -5M Q4 '23: -9.3M Q1 '24: -15.4M Q2 '24: -10.9M Q3 '24: -12.9M Q4 '24: -6.8M Q1 '25: -10.6M Q2 '25: 15.5M Q3 '25: 5.8M Q4 '25: -3.9M Q1 '26: 110.4M Q2 '26: -468K Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue Quarterly

0 4M 8M 12M Q1 '18: 1.5M Q2 '18: 1.7M Q3 '18: 1.4M Q4 '18: 1.6M Q1 '19: 1.9M Q2 '19: 2.4M Q3 '19: 2.7M Q4 '19: 3.6M Q1 '20: 3.8M Q2 '20: 3.1M Q3 '20: 3.4M Q4 '20: 4.3M Q1 '21: 3.9M Q2 '21: 7.5M Q3 '21: 11.2M Q4 '21: 9.5M Q1 '22: 8.2M Q2 '22: 7.6M Q3 '22: 7.2M Q4 '22: 7.7M Q1 '23: 6.4M Q2 '23: 7.8M Q3 '23: 6.4M Q4 '23: 2.2M Q1 '24: 6M Q2 '24: 5.7M Q3 '24: 4.5M Q4 '24: 4.7M Q1 '25: 4.8M Q2 '25: 4.9M Q3 '25: 5.8M Q4 '25: 5.4M Q1 '26: 6.2M Q2 '26: 6.1M Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating Cash Flow Quarterly

-70M 0 70M 140M 210M Q3 '16: -8.8M Q4 '16: -18M Q1 '17: -11.5M Q2 '17: -23.9M Q3 '17: -25.1M Q4 '17: -20.9M Q1 '18: -27.8M Q2 '18: -24.1M Q3 '18: -24.8M Q4 '18: -22.2M Q1 '19: -25.3M Q2 '19: -28.3M Q3 '19: -16.3M Q4 '19: -25.1M Q1 '20: -21.9M Q2 '20: -17.4M Q3 '20: -23.9M Q4 '20: -20.5M Q1 '21: -21.7M Q2 '21: -34.5M Q3 '21: -21.7M Q4 '21: -38.7M Q1 '22: -46.9M Q2 '22: -41.4M Q3 '22: -43.3M Q4 '22: -47.8M Q1 '23: -43.2M Q2 '23: -33.3M Q3 '23: -16.8M Q4 '23: -34.9M Q1 '24: -25.4M Q2 '24: -21.8M Q3 '24: -20.1M Q4 '24: -12.9M Q1 '25: -19.6M Q2 '25: -27.6M Q3 '25: -6.1M Q4 '25: -12.5M Q1 '26: 203.9M Q2 '26: -59.3M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow Quarterly

-60M -40M -20M 0 20M 40M 60M Q2 '14: -4M Q3 '14: -2.7M Q4 '14: -3.5M Q1 '15: -1.9M Q2 '15: -6.2M Q3 '15: -5.3M Q4 '15: -7.3M Q1 '16: -13.9M Q2 '16: -9.4M Q3 '16: -10.3M Q4 '16: -18.6M Q1 '17: -11.7M Q2 '17: -24.1M Q3 '17: -25.6M Q1 '18: -28.6M Q2 '18: -27.9M Q3 '18: -26.9M Q4 '18: -22.5M Q1 '19: -25.6M Q2 '19: -29M Q3 '19: -16.8M Q4 '19: -25.9M Q1 '20: -22.4M Q2 '20: -18.6M Q3 '20: -24.4M Q4 '20: -21.2M Q1 '21: -22.1M Q2 '21: -36.1M Q3 '21: -22.2M Q4 '21: -40.7M Q1 '22: -48.2M Q2 '22: -41.7M Q3 '22: -44.3M Q4 '22: -47.9M Q1 '23: -43.2M Q2 '23: -33.3M Q3 '23: -16.8M Q4 '23: -35M Q3 '24: -20.1M Q4 '24: -12.9M Q2 '15 Q3 '16 Q1 '18 Q2 '19 Q3 '20 Q4 '21 Q1 '23 Q4 '24

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 35M 70M 105M Q1 '18: 42.5M Q1 '19: 63.8M Q1 '20: 63.5M Q1 '21: 80.9M Q2 '21: 81M Q3 '21: 81.3M Q1 '22: 86.3M Q2 '22: 88.7M Q3 '22: 6M Q1 '23: 101.9M Q2 '23: 7.4M Q3 '23: 7.5M Q1 '24: 17.2M Q2 '24: 18.3M Q3 '24: 19.7M Q1 '25: 26.5M Q2 '25: 29.8M Q3 '25: 33.1M Q1 '26: 38.4M Q2 '26: 31.8M Q1 '19 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-15.00 -10.00 -5.00 0.00 5.00 10.00 15.00 Q2 '16: -1.38 Q3 '16: -1.24 Q4 '16: -1.37 Q1 '17: -1.36 Q2 '17: -1.48 Q3 '17: -1.83 Q4 '17: -1.65 Q1 '18: -1.84 Q2 '18: -1.91 Q3 '18: -1.61 Q4 '18: -1.91 Q1 '19: -1.40 Q2 '19: -1.14 Q3 '19: -0.99 Q4 '19: -0.71 Q1 '20: -0.92 Q2 '20: -0.87 Q3 '20: -0.85 Q4 '20: -0.64 Q1 '21: -0.56 Q2 '21: -0.41 Q3 '21: -0.47 Q4 '21: -0.79 Q1 '22: -0.86 Q2 '22: -1.08 Q3 '22: -4.93 Q4 '22: -9.37 Q1 '23: -9.40 Q2 '23: -12.79 Q3 '23: -9.62 Q4 '23: -5.33 Q1 '24: -6.16 Q2 '24: -3.24 Q3 '24: -3.06 Q4 '24: -2.79 Q1 '25: -2.23 Q2 '25: -1.05 Q3 '25: -0.18 Q4 '25: -0.07 Q1 '26: 3.23 Q2 '17 Q3 '18 Q4 '19 Q1 '21 Q2 '22 Q3 '23 Q4 '24 Q1 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.